1. Home /
  2. Biotechnology

Biotechnology

What's Next for Biogen After It Terminates Trials for Alzheimer's Drug?

What's Next for Biogen After It Terminates Trials for Alzheimer's Drug?

Biogen has to now be considered a more likely buyout target given the breadth of its product portfolio.

Pfizer Acquires Gene Therapy Portfolio in Deal that Could Total $636 Million

Pfizer Acquires Gene Therapy Portfolio in Deal that Could Total $636 Million

Pfizer pays $51 million up front for a 15% stake in French biopharmaceutical company Vivet.

Sage Therapeutics Surges on FDA Approval of Postpartum Depression Drug

Sage Therapeutics Surges on FDA Approval of Postpartum Depression Drug

First treatment for common childbirth complication wins FDA OK.

Biogen Could Go Either Way - Mixed Indicators and Charts

Biogen Could Go Either Way - Mixed Indicators and Charts

Let's check to see what can be gleaned.

Edwards Lifesciences Gains on Positive Heart Trial Results

Edwards Lifesciences Gains on Positive Heart Trial Results

The medical research and device company announces positive results from its recent aortic valve surgical treatment trial.

My Post-Earnings Assessment of 2 Biotech Stocks

My Post-Earnings Assessment of 2 Biotech Stocks

Let's look at a couple of companies we have covered on these pages before.

Sarepta Therapeutics' Charts Look Risky

Sarepta Therapeutics' Charts Look Risky

In a red flag for investors, the charts show sellers are getting more aggressive with Sarepta.

Infusion Therapy Firm BioScrip to Buy Rival Option Care

Infusion Therapy Firm BioScrip to Buy Rival Option Care

BioScrip agrees to buy rival Option Care Enterprises, creating one of the largest independent home-therapy companies in the U.S.

What Is the Internet of Things and Why Is It Essential in 2019?

What Is the Internet of Things and Why Is It Essential in 2019?

The Internet of Things promises to merge the physical and data worlds together. This is why that's a good thing.

Positive Breadth Helps Momentum Continue Despite Boeing's Woes

Positive Breadth Helps Momentum Continue Despite Boeing's Woes

Strength in Apple and other FANG names are pluses, as are pockets of action in gold mining, cannabis, biotechnology and shipping.